IRVINE, Calif., Oct. 21, 2009 (GLOBE NEWSWIRE) -- SenoRx (Nasdaq:SENO) today announced that it ranked among the fastest growing companies in Deloitte's 2009 Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications and life sciences and clean technology companies in North America. Rankings are based on percentage revenue growth during the five year period from 2004 to 2008. SenoRx grew 240 percent during this period, ranking it #460 of the list.
Lloyd Malchow, SenoRx Chairman and Chief Executive Officer, credits the significant progress that the company has made in creating a strong presence in the growing global market for interventional diagnostic and therapeutic products for breast care. Malchow said, "SenoRx has built its business over the past five years by leveraging its sales force to call on an emerging, consolidating customer base with an offering of innovative products that provide minimally invasive solutions in the breast cancer area."
Fast 500 Selection and Qualifying Criteria
Technology Fast 500(TM) provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Technology Fast 500(TM) website, and public company database research conducted by Deloitte LLP. Technology Fast 500(TM) award winners for 2009 are selected based on percentage fiscal year revenue growth during the five year period from 2004 to 2008.
In order to be eligible for Technology Fast 500(TM) recognition, companies must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues. Using other companies' technology or intellectual property in a unique way does not satisfy this requirement. Consulting companies, professional service firms, etc. are not eligible unless they have proprietary technology that contributes to a significant portion of their operating revenues.
Technology Fast 500(TM) award eligibility requirements include a base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, these revenues must have more than doubled between 2004 and 2008. Also companies must be in business for a minimum of five years, and be headquartered within North America.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(R) vacuum-assisted breast biopsy system and Contura(TM) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605